Heard about peptides? Here's what's actually known

Spend any time around a gym, or scrolling through athletes on social media, and you'll run into names that sound like license plates: BPC-157, TB-500, MOTS-c. They're peptides, and they're sold as a shortcut to heal a tendon faster, bounce back from a muscle injury or drop fat. In July 2026, a committee at the agency that decides which drugs can be sold in the United States voted on them, and that vote put them in the headlines.

This isn't a recommendation, and it isn't a warning. It's a plain explanation of what they are, how people use them and what's actually known about them in humans, so the next time someone brings them up you'll know what you're hearing.

What a peptide is

A peptide is a short chain of amino acids, the same building blocks your body uses to make proteins. Think of a protein as a long necklace and a peptide as a bracelet with only a few beads. Your body makes plenty of them, and some act as messengers between organs. Insulin is one. Calling something a peptide tells you how it's built, not whether it's good or bad for you.

Some peptides are drugs backed by years of trials, like semaglutide, Ozempic's active ingredient. In the STEP 1 trial (The New England Journal of Medicine, 2021), 1,961 adults with obesity took semaglutide or placebo for 68 weeks. Average weight loss was 14.9% on the drug and 2.4% on placebo. That's the evidence behind an approved drug and the bar for everything else, supplements included: creatine has been tested in people over and over; most of these peptides haven't.

The names you keep hearing

BPC-157 is a synthetic fragment of a protein first isolated from human gastric juice. TB-500 is a lab-made version of part of thymosin beta-4, a protein the body uses when it repairs tissue. Those two are the ones linked to sore tendons, torn ligaments and strained muscles. Online sellers often bundle them together, too.

MOTS-c is made inside the mitochondria, the power plants of your cells. When the FDA reviewed this group in 2026, MOTS-c had been put forward for obesity and osteoporosis, Semax for stroke-related brain injury and migraine, epitalon for insomnia and KPV for wound healing and inflammation. None of the six is an approved drug.

How people use them

Most are sold to be injected under the skin, though you'll also find nasal sprays, creams and capsules. They're bought online, in vials labeled "for research use only" or "not for human consumption."

That label matters more than it looks. In an August 2026 episode of the mindbodygreen podcast, researcher Rachele Pojednic called it legal cover for gray-market products: if the vial says it isn't meant for humans, the company selling it carries no liability when something goes wrong. Nobody knows what amount is safe or for how long, either, because the human data barely exists.

What the FDA is, and what it voted on in July 2026

The FDA, short for Food and Drug Administration, is the federal agency that decides which medicines can be sold in the United States. Before it approves one, it reviews the trials showing that the drug works and that it's safe. In the European Union, the European Medicines Agency plays that role.

On July 23 and 24, 2026, an FDA advisory committee voted on whether seven peptides should go on the list of ingredients that pharmacies can use to mix custom medications. It backed six of them by narrow margins, including an 8 to 6 vote for BPC-157, going against the agency's own scientists, who had recommended leaving all seven off.

The vote doesn't make anything legal. Advisory committees only give advice, and for anything to change the FDA would have to propose a rule, open it to public comment and then finalize it. As of October 2, 2026, the Federal Register, where the government publishes those proposals, showed no such rule.

One detail matters if you train. BPC-157 was nominated for ulcerative colitis, Crohn's disease, celiac disease and tendinitis, yet the FDA only evaluated ulcerative colitis. It set tendinitis aside because the nomination didn't include enough information and because the agency found no clinical studies in those patients. In other words, the use BPC-157 is best known for, getting over an injury, was never even reviewed.

What the research says about injuries

In 2025, HSS Journal, published by the Hospital for Special Surgery in New York, ran a systematic review of BPC-157 in sports medicine. It pulled together 36 studies going back to 1993, and only one of them involved people. Everything else was done in animals or in the lab, where the peptide improved healing in muscles, tendons, ligaments and bone.

The human study reviewed the records of 12 patients with chronic knee pain given BPC-157 injections into the joint. Seven reported relief lasting more than six months. Without a comparison group, the peptide's effect can't be separated from time or expecting to feel better. The review found no clinical safety data in humans. Since February 2026, the first controlled trial in a sports injury has tested BPC-157 against placebo on grade II hamstring strains; main results aren't expected before 2027.

A critical review in the International Journal of Molecular Sciences, published in September 2026, went through the rodent studies on BPC-157 and injuries caused by cut-off blood flow. The signals were positive, but the studies were short, often used a single dose and described their risk of bias poorly. The author's verdict: BPC-157 is a hypothesis worth testing further, not an established treatment, and getting to human use would take independent replication and, eventually, controlled trials in people.

TB-500 and the rest are in much the same spot. In August 2026, doctors at Brigham and Women's Hospital in Boston reviewed peptides used for tissue repair and chronic pain in Current Pain and Headache Reports. They concluded that most aren't FDA-approved and that clinical evidence in humans is limited.

What worries the FDA itself

In the briefing document it prepared for that vote, the FDA spelled out its concerns about BPC-157. The substance isn't well characterized chemically, and there's no data on how it's absorbed when injected under the skin. Like any injected peptide, it could also trigger an immune reaction if it contains impurities or if its molecules clump together. The handful of human studies the agency found were short and small, with little safety information.

If you compete, there's one more thing to know. The World Anti-Doping Agency's 2026 list names BPC-157 among non-approved substances and puts thymosin beta-4 and its derivatives, TB-500 included, among banned growth factors. Both categories are prohibited in and out of competition.

Three questions before you buy the promise

If an injury holds you back and someone mentions peptides, ask three questions. Is there a controlled trial in people with your injury? Which drug agency approved it? Who vouches for what's in the vial? Based on studies published by October 2026, the answers for BPC-157 and TB-500 in tendon or muscle injuries are no, none and nobody. If you train at Gym Triple X, keep them handy. They work just as well on any remedy promising a faster recovery.

None of this replaces the people treating you. If an injury is dragging on, your doctor or physical therapist is the one who can judge what makes sense for you, and any decision about a drug, approved or not, belongs with them. And if what hurts is your muscles a day or two after a workout rather than an actual injury, what really eases next-day muscle soreness has far more science behind it.

Coming back from an injury takes patience and someone who watches how you move as you rebuild your training. If you'd rather not do it alone, a personal trainer on the Costa del Sol can adjust each week to what your body is ready for, in step with whoever is handling your rehab.